[go: up one dir, main page]

EP0846116A1 - 1-benzoyl-2-(indolyl-3-alkyl)-piperazine derivatives as neurokinin receptor antagonists - Google Patents

1-benzoyl-2-(indolyl-3-alkyl)-piperazine derivatives as neurokinin receptor antagonists

Info

Publication number
EP0846116A1
EP0846116A1 EP96915200A EP96915200A EP0846116A1 EP 0846116 A1 EP0846116 A1 EP 0846116A1 EP 96915200 A EP96915200 A EP 96915200A EP 96915200 A EP96915200 A EP 96915200A EP 0846116 A1 EP0846116 A1 EP 0846116A1
Authority
EP
European Patent Office
Prior art keywords
compound
salt
alkyl
formula
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP96915200A
Other languages
German (de)
French (fr)
Inventor
Masaaki Matsuo
Daijiro Hagiwara
Takashi Manabe
Nobukiyo Konishi
Shinji Shigenaga
Kenji Murano
Hiroshi Matsuda
Hiroshi Miyake
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Publication of EP0846116A1 publication Critical patent/EP0846116A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • the present invention relates to new piperazine derivatives and a pharmaceutically acceptable salt thereof.
  • new piperazine derivatives and a pharmaceutically acceptable salt thereof which have pharmacological activities such as Tachykinin antagonism, especially Substance P antagonism, Neurokinin A antagonism, Neurokinin B antagonism, and the like, to a process for preparation thereof, to a pharmaceutical composition comprising the same, and to a use of the same as a medicament.
  • one object of the present invention is to provide new and useful piperazine derivatives and a pharmaceutically acceptable salt thereof which have pharmacological activities such as Tachykinin antagonism, especially Substance P antagonism, Neurokinin A antagonism, Neurokinin B antagonism, and the like.
  • Another object of the present invention is to provide a process for the preparation of said piperazine derivatives ⁇ and a salt thereof.
  • a further object of the present invention is to provide a pharmaceutical composition comprising, as an active ingredient, said piperazine derivatives and a pharmaceutically acceptable salt thereof.
  • Still further object of the present invention is to provide a use of said piperazine derivatives or a pharmaceutically acceptable salt thereof as Tachykinin antagonist, especially Substance P antagonist, Neurokinin A antagonist or Neurokinin B antagonist, useful for treating or preventing Tachykinin-mediated diseases, for example, respiratory diseases such as asthma, bronchitis, rhinitis, cough, expectoration, and the like; ophthalmic diseases such as conjunctivitis, vernal conjunctivitis, and the like; cutaneous diseases such as contact dermatitis, atopic dermatitis, urticaria, and other eczematoid dermatitis, and the like; inflammatory diseases such as rheumatoid arthritis, osteoarthritis, and the like; pains or aches (e.g., migraine, headache, toothache cancerous pain, back pain, etc.); and the like in human being or animals.
  • respiratory diseases such as asthma, bronchitis, rhinitis, cough, expectoration
  • the object compound of the present invention is the compound of the following formula (I) :
  • the other object compound of the present invention can be represented by the following general formula (Ig) :
  • R 1 is trihalo (lower)alkyl
  • R ⁇ is trihalo (lower)alkyl
  • R J is mdolyl(lower)alkyl
  • -A- is -CH' or - -flC-*CH 2 - and
  • R is hydrogen or lower alkoxycarbonyl
  • R 6 is hydrogen or lower alkanoyl
  • R 7 is hydrogen, lower alkyl, lower alkanoyl, lower alkoxycarbonyl, lower alkoxy(lower)alkanoyl, cyclo(lower)alkylcarbonyl, aroyl or lower alkylsulfonyl, or its pharmaceutically acceptable salt.
  • the object compounds can be prepared by processes which are illustrated in the following schemes. - t -
  • Suitable salts and pharmaceutically acceptable salts of the starting and object compounds are conventional non-toxic salt and include an acid addition salt such as an organic acid salt (e.g. acetate, trifluoroacetate, fumarate, maleate, tartrate, methanesulfonate, benzenesulfonate, formate, toluenesulfonate, etc.), an inorganic acid salt (e.g. hydrochloride, hydrobromide, hydroiodide, sulfate, nitrate, phosphate, etc.), or a salt with an amino acid (e.g. arginine, aspartic acid, glutamic acid, etc.), or a metal salt such as an alkali metal salt (e.g.
  • an organic acid salt e.g. acetate, trifluoroacetate, fumarate, maleate, tartrate, methanesulfonate, benzenesulfonate, formate, toluenesulfonate
  • an alkaline earth metal salt e.g. calcium salt, magnesium salt, etc.
  • an ammonium salt e.g. sodium salt, potassium salt, etc.
  • an organic base salt e.g. trimethylamine salt, triethylamine salt, pyridine salt, picoline salt, dicyclohexylamine salt, N,N'-dibenzylethylenediamine salt, etc.
  • an organic base salt e.g. trimethylamine salt, triethylamine salt, pyridine salt, picoline salt, dicyclohexylamine salt, N,N'-dibenzylethylenediamine salt, etc.
  • Suitable "lower alkyl” and “lower alkyl moiety" in the terms “indolyl(lower)alkyl” and “lower alkylsulfonyl” is straight or branched one having 1 to 6 carbon atom(s) and may include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, hexyl and the like.
  • Suitable “trihalo (lower) alkyl” may include trichloromethyl, tribromomethyl, trifluoromethyl and the like.
  • Suitable "lower alkoxy” and “lower alkoxy moiety" in the terms “lower alkoxycarbonyl” and “lower alkoxy(lower)alkanoyl” may include methoxy, ethoxy, isopropyloxy, butoxy and the like.
  • Suitable "lower alkanoyl” and “lower alkanoyl moiety" in the term “lower alkoxy(lower)alkanoyl” may include formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, hexanoyl, pivaloyl and the like.
  • Suitable "cyclo (lower)alkyl moiety" in the term “cyclo(lower) alkylcarbonyl” may include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.
  • Suitable “aroyl” may include benzoyl, toluoyl, naphthoyl and the like.
  • Suitable “leaving group” may include hydroxy, reactive group derived from hydroxy and the like.
  • Suitable “reactive group derived from hydroxy” may include acid residue and the like.
  • Suitable “acid residue” may include halogen (e.g. fluoro, chloro, bromo, iodo) , acyloxy (e.g. acetoxy, tosyloxy, mesyloxy, etc.) and the like.
  • halogen e.g. fluoro, chloro, bromo, iodo
  • acyloxy e.g. acetoxy, tosyloxy, mesyloxy, etc.
  • the object compound (I) or a salt thereof can be prepared by reacting a compound (II) or its reactive derivative at the carboxy group or a salt thereof with a compound (III) or its reactive derivative at the amino group or a salt thereof.
  • Suitable reactive derivative at the carboxy group of the compound (II) may include an acid halide, an acid anhydride, an activated amide, an activated ester, and the like.
  • Suitable examples of the reactive derivatives may be an acid chloride; an acid azide; a mixed acid anhydride with an acid such as substituted phosphoric acid [e.g. dialkylphosphoric acid, phenylphosphoric acid, diphenylphosphoric acid, dibenzylphosphoric acid, halogenated phosphoric acid, etc.], dialkylphosphorous acid, sulfurous acid, thiosulfuric acid, sulfuric acid, sulfonic acid [e.g. methanesulfonic acid, etc.], aliphatic carboxylic acid [e.g. acetic acid, propionic acid, butyric acid, isobutyric acid, pivalic acid, pentanoic acid, isopentanoic acid,
  • substituted phosphoric acid e.g. dialkylphosphoric
  • cvanomethyl ester methoxymethyl ester, dimethyliminomethyl [ ester, vinyl ester, propargyl ester, p-nitrophenyl ester, 2,4-dinitrophenyl ester, trichlorophenyl ester, pentachlorophenyl ester, mesylphenyl ester, phenylazophenyl ester, phenyl thioester, p-nitrophenyl thioester, p-cresyl thioester, carboxymethyl thioester, pyranyl ester, pyridyl ester, piperidyl ester, 8-quinolyl thioester, etc.], or an ester with a N-hydroxy compound [e.g.
  • Suitable reactive derivative at the amino group of the compound (III) may include Schiff's base type imino or its tautomeric enamine type isomer formed by the reaction of the compound (III) with a carbonyl compound such as aldehyde, ketone or the like; a silyl derivative formed by the reaction of the compound (III) with a silyl compound such as bis (trimethylsilyl)acetamide, mono (trimethylsilyl) acetamide, bis (trimethylsilyl)urea or the like; a derivative formed by reaction of the compound (III) with phosphorus trichloride or phosgene and the like.
  • the reaction is usually carried out in a conventional solvent such as water, alcohol [e.g. methanol, ethanol, etc.], acetone, 2-butanone, dioxane, acetonitrile, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, pyridine or any other organic solvent which does not adversely influence the reaction, or the mixture thereof.
  • a conventional solvent such as water, alcohol [e.g. methanol, ethanol, etc.], acetone, 2-butanone, dioxane, acetonitrile, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, pyridine or any other organic solvent which does not adversely influence the reaction, or the mixture thereof.
  • the reaction when the compound (II) is used in a free acid form or its salt form, the reaction is preferably carried out in the presence of a conventional condensing agent such as N,N'-dicyclohexylcarbodiimide; N-cyclohexyl-N'-morpholinoethylcarbodiimide; N-cyclohexyl-N'- (4-diethylaminocyclohexyl) carbodiimide; N,N'-diethylcarbodiimide; N,N'-diisopropylcarbodiimide; N-ethyl-N'- (3-dimethylaminopropyl)carbodiimide; pentamethyleneketene-N-cyclohexylimine; diphenylketene-N-cyclohexylimine; ethoxyacetylene; 1-alkoxy-l-chloroethylene; trialkyl phosphite; ethyl poly
  • the reaction may also be carried out in the presence of an inorganic or organic base such as an alkali metal bicarbonate, tri (lower)alkylamine, pyridine, N-(lower) alkylmorpholine, N,N-di (lower)alkylbenzylamine, or the like.
  • an inorganic or organic base such as an alkali metal bicarbonate, tri (lower)alkylamine, pyridine, N-(lower) alkylmorpholine, N,N-di (lower)alkylbenzylamine, or the like.
  • the reaction temperature is not critical, and the reaction is usually carried out under cooling to warming.
  • the object compound (If) can be prepared by reacting the compound (I) or a salt thereof other than fumaric acid salt thereof with fumaric acid.
  • the reaction is usually carried out in a conventional solvent such as water, alcohol [e.g. methanol, ethanol, etc.], acetone, 2-butanone, dioxane, acetonitrile, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, pyridine or any other organic solvent which does not adversely influence the reaction, or the mixture thereof.
  • a conventional solvent such as water, alcohol [e.g. methanol, ethanol, etc.], acetone, 2-butanone, dioxane, acetonitrile, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, pyridine or any other organic solvent which does not adversely influence the reaction, or the mixture thereof.
  • the reaction temperature is not critical, and the reaction is usually carried out under cooling to warming.
  • the object compound (Ig') or a salt thereof can be prepared by reacting the compound (IV) or its reactive derivative at the imino group or a salt thereof with the compound (V) or a salt thereof.
  • Suitable reactive derivative at the imino group of the compound (IV) may include Schiff's base type imino or its tautomeric enamine type isomer formed by the reaction of the compound (IV) with a carbonyl compound such as aldehyde, ketone or the like; a silyl derivative formed by the reaction of the compound (IV) with a silyl compound such as bis (trimethylsilyl) acetamide, mono(trimethylsilyl)acetamide. bis (trimethylsilyl)urea or the like; a derivative formed by reaction of the compound (IV) with phosphorus trichloride or phosgene and the like.
  • This reaction is usually carried out in a solvent such as alcohol [e.g. methanol, ethanol, etc.], dichloromethane, benzene, N,N-dimethylformamide, tetrahydrofuran, diethyl ether or any other solvent which does not adversely affect the reaction.
  • a solvent such as alcohol [e.g. methanol, ethanol, etc.], dichloromethane, benzene, N,N-dimethylformamide, tetrahydrofuran, diethyl ether or any other solvent which does not adversely affect the reaction.
  • the raction may be carried out in the presence of an inorganic or an organic base such as an alkali metal hydroxide [e.g. sodium hydroxide, potassium hydroxide, etc.], an alkali metal carbonate [e.g. sodium carbonate, potassium carbonate, etc.], an alkali metal bicarbonate [e.g. sodium bicarbonate, potassium bicarbonate, etc.], alkali metal hydride [e.g. sodium hydride, potassium hydride, etc.], tri (lower) alkylamine [e.g. trimethylamine, triethylamine, diisopropylethylamine, etc.], pyridine or its derivative [e.g. picoline, lutidine, 4-dimethylaminopyridine, etc.], or the like.
  • an alkali metal hydroxide e.g. sodium hydroxide, potassium hydroxide, etc.
  • an alkali metal carbonate e.g. sodium carbonate, potassium carbonate, etc.
  • the reaction temperature is not critical, and the reaction can be carried out under cooling, at room temperature or under warming or heating.
  • the compound (Ig") or a salt thereof can be prepared by reacting a compound (IV) or its reactive derivative at the imino group or a salt thereof with a compound (VI) or its reactive derivative at the carboxy group or a salt thereof.
  • the reaction can be carried out in the manner disclosed in Preparation 10 or similar manners thereto.
  • the object compounds of the present invention have pharmacological activities such as Tachykinin antagonism, especially Substance P antagonism, Neurokinin A antagonism or Neurokinin B antagonism, and therefore are useful for treating or preventing Tachykinin-mediated diseases, particularly Substance P-mediated diseases, for example, respiratory diseases such as asthma, bronchitis (e.g.
  • ophthalmic diseases such as conjunctivitis, vernal conjunctivitis, and the like
  • cutaneous diseases such as contact dermatitis, atopic dermatitis, urticaria, and other eczematoid dermatitis, and the like
  • inflammatory diseases such as rheumatoid arthritis, osteoarthritis, and the like
  • pains or aches e.g. migraine, headache, cluster headache, toothache, cancerous pain, back pain, neuralgia, etc.
  • the object compounds of the present invention are useful for treating or preventing ophthalmic diseases such as glaucoma, uveitis, and the like; gastrointestinal diseases such as ulcer, ulcerative colitis, irritable bowel syndrome, food allergy, and the like; inflammatory diseases such as nephritis, and the like, circulatory diseases such as hypertension, angina pectoris, cardiac failure, thrombosis, Raynaud's disease, and the like; epilepsy; spastic paralysis; pollakiuria; cystitis; bladder detrusor hyperreflexia; urinary incontinence; Parkinson- diseases; dementia; AIDS related dementia; Alzheimer's diseases; Down's syndrome; Huntington's chorea; carcinoid syndrome; disorders related to immune enhancement or suppression; disorders caused by Helicobacter pylori or another spiral urease-positive gram-negative bacterium; sunburn; angiogenesis or diseases caused by angiogenesis; and the like.
  • ophthalmic diseases such as glaucoma,
  • the object compounds of the present invention are useful for treating or preventing chronic obstructive pulmonary diseases, particularly chronic pulmonary emphysema; blinkis; proliferative vitreoretinopathy; psoriasis; inflammatory intestinal diseases, particularly Crohn's diseases; hepatitis; superficial pain on congelation, burn, herpes zoster or diabetic neuropathy; tenalgia attended to hyperlipidemia; postoperative neuroma, particularly of mastectomy; vulvar vestibulitis; he odialysis-associated itching; lichen planus; laryngopharyngitis; bronchiectasis; coniosis; whooping cough; pulmonary tuberculosis; cystic fibrosis; e esis; mental diseases, particularly anxiety, depression, dysthymic disorders and schizophrenia; demyelinating diseases such as multiple sclerosis and amyotrophic lateral sclerosis; attenuation of morphine withdrawal; oe
  • the object compounds of the present invention can be used in a form of pharmaceutical preparation containing one of said compound, as an active ingredient, in admixture with a pharmaceutically acceptable carrier such as an organic or inorganic solid or liquid excipient suitable for oral, parenteral, external including topical, enteral, intravenous, intramuscular, inhalant, nasal, intraarticular, intraspinal, transtracheal or transocular administration.
  • a pharmaceutically acceptable carrier such as an organic or inorganic solid or liquid excipient suitable for oral, parenteral, external including topical, enteral, intravenous, intramuscular, inhalant, nasal, intraarticular, intraspinal, transtracheal or transocular administration.
  • the pharmaceutical preparations may be solid, semi-solid or solutions such as capsules, tablets, pellets, dragees, powders, granules, suppositories, ointments, creams, lotions, inhalants, injections, cataplasms, gels, tapes, eye drops, solution, syrups, aerosols, suspension, emulsion, or the like.
  • auxiliary substances stabilizing agents, wetting or emulsifying agents, buffers and other commonly used additives.
  • an average single dose of about 0.1 mg, 1 mg, 10 mg, 50 mg, 100 mg, 250 mg, 500 mg and 1000 mg of the object compounds may be effective for treating Tachykinin-mediated diseases such as asthma and the like.
  • amounts between 0.1 mg/body and about 1,000 mg/body may be administered per day.
  • CHO cells permanently expressing h-NK-, receptors were harvested and homogenized with a Dounce homogenizer at 4°C in a buffer (0.25 M sucrose, 25 M Tris-HCl pH 7.4, 10 mM MgCl 2 ,
  • Cell membranes (6 ⁇ g/ml) were incubated with 12 ⁇ I-BH- Substance P (0.1 nM) with or without test compounds in 0.25 ml of Medium 2 (50 mM Tris-HCl pH 7.4, 5 mM MnCl 2 , 20 ⁇ g/ml chvmostatin, 40 ⁇ g/ml bacitracin, 4 ⁇ g/ml leupeptin, 5 ⁇ g/ml p-APMSF, 200 ⁇ g/ml BSA) at 22°C for 90 minutes. At the end of the incubation period, the content was quickly filtered over a Wahtman GF/C glass filter (pretreated with 0.1% polyethylene imine for 3 hours prior to use) under aspiration.
  • Medium 2 50 mM Tris-HCl pH 7.4, 5 mM MnCl 2 , 20 ⁇ g/ml chvmostatin, 40 ⁇ g/ml bacitracin, 4 ⁇ g/ml le
  • the object compound of the present invention is also superior in stability and the like.
  • Example 5 The following piperazine derivatives (Table 1) were prepared by the similar manner to that of the each Example

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

This invention relates to compounds of generic formula (I), to a process for preparation thereof, to a pharmaceutical composition comprising the same, and to a use of the same as a medicament. In formula (Ig), R1 is trihalo(lower)alkyl, R2 is trihalo(lower)alkyl, R3 is indolyl(lower)alkyl, -A- is -CH¿2?- or (a), and -R?4¿ is (b), (c) or (d) in which R5 is hydrogen or lower alkoxycarbonyl, R6 is hydrogen or lower alkanoyl, R7 is hydrogen, lower alkyl, lower alkanoyl, lower alkoxycarbonyl, lower alkoxy(lower)alkanoyl, cyclo(lower)alkylcarbonyl, aroyl or lower alkylsulfonyl, or its pharmaceutically acceptable salt.

Description

D E S C R I P T I O N
l-BENZ0YL-2-(IND0LYL-3-ALKYL)-PIPERAZINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS
TECHNICAL FIELD
The present invention relates to new piperazine derivatives and a pharmaceutically acceptable salt thereof.
More particularly, it relates to new piperazine derivatives and a pharmaceutically acceptable salt thereof which have pharmacological activities such as Tachykinin antagonism, especially Substance P antagonism, Neurokinin A antagonism, Neurokinin B antagonism, and the like, to a process for preparation thereof, to a pharmaceutical composition comprising the same, and to a use of the same as a medicament.
Accordingly, one object of the present invention is to provide new and useful piperazine derivatives and a pharmaceutically acceptable salt thereof which have pharmacological activities such as Tachykinin antagonism, especially Substance P antagonism, Neurokinin A antagonism, Neurokinin B antagonism, and the like.
Another object of the present invention is to provide a process for the preparation of said piperazine derivatives ■and a salt thereof.
A further object of the present invention is to provide a pharmaceutical composition comprising, as an active ingredient, said piperazine derivatives and a pharmaceutically acceptable salt thereof.
Still further object of the present invention is to provide a use of said piperazine derivatives or a pharmaceutically acceptable salt thereof as Tachykinin antagonist, especially Substance P antagonist, Neurokinin A antagonist or Neurokinin B antagonist, useful for treating or preventing Tachykinin-mediated diseases, for example, respiratory diseases such as asthma, bronchitis, rhinitis, cough, expectoration, and the like; ophthalmic diseases such as conjunctivitis, vernal conjunctivitis, and the like; cutaneous diseases such as contact dermatitis, atopic dermatitis, urticaria, and other eczematoid dermatitis, and the like; inflammatory diseases such as rheumatoid arthritis, osteoarthritis, and the like; pains or aches (e.g., migraine, headache, toothache cancerous pain, back pain, etc.); and the like in human being or animals.
DISCLOSURE OF INVENTION
The object compound of the present invention is the compound of the following formula (I) :
namely (2R)-1-[3,5-bis (trifluoromethyl)benzoyl]-2- (lH-indol- 3-ylmethyl)-4-[N-(4-methyl-l-piperazinyl) carbamoylmethyl]- piperazine, or fumaric acid salt thereof, namely (2R)-1-[3,5- bis(trifluoromethyl)benzoyl]-2-(lH-indol-3-ylmethyl)-4-[N- (4- methyl-1-piperazinyl)carbamoylmethyl]piperazine fumarate [hereinafter referred to briefly as compound (If) ] .
The other object compound of the present invention can be represented by the following general formula (Ig) :
wherein
R1 is trihalo (lower)alkyl,
R^ is trihalo (lower)alkyl,
RJ is mdolyl(lower)alkyl,
0
-A- is -CH' or - -flC-*CH2- and
in which R is hydrogen or lower alkoxycarbonyl, R6 is hydrogen or lower alkanoyl,
R7 is hydrogen, lower alkyl, lower alkanoyl, lower alkoxycarbonyl, lower alkoxy(lower)alkanoyl, cyclo(lower)alkylcarbonyl, aroyl or lower alkylsulfonyl, or its pharmaceutically acceptable salt.
According to the present invention, the object compounds can be prepared by processes which are illustrated in the following schemes. - t -
Process 1
(ID or its reactive derivative at the carboxy group or a salt thereof
(I) or a salt thereof
Process 2
(I) or a salt thereof other than fumaric acid salt thereof
(if )
P ocess 3
(IV) (igJ or its reactive derivative or a salt thereof at the imino group or a salt thereof
Process 4
HOOC-A-L-R4
(IV) dg") or its reactive derivative or a salt thereof at the imino group or a salt thereof wherein R , R , R3 and R4 are each as defined above; W is a leaving group.
Suitable salts and pharmaceutically acceptable salts of the starting and object compounds are conventional non-toxic salt and include an acid addition salt such as an organic acid salt (e.g. acetate, trifluoroacetate, fumarate, maleate, tartrate, methanesulfonate, benzenesulfonate, formate, toluenesulfonate, etc.), an inorganic acid salt (e.g. hydrochloride, hydrobromide, hydroiodide, sulfate, nitrate, phosphate, etc.), or a salt with an amino acid (e.g. arginine, aspartic acid, glutamic acid, etc.), or a metal salt such as an alkali metal salt (e.g. sodium salt, potassium salt, etc.) and an alkaline earth metal salt (e.g. calcium salt, magnesium salt, etc.), an ammonium salt, an organic base salt (e.g. trimethylamine salt, triethylamine salt, pyridine salt, picoline salt, dicyclohexylamine salt, N,N'-dibenzylethylenediamine salt, etc.), or the like.
In the above and subsequent descriptions of the present specification, suitable examples and illustrations of the various definitions which the present invention include within the scope thereof are explained in detail as follows. The term "lower" is intended to mean 1 to 6, preferably
1 to 4 carbon atom(s), unless otherwise indicated.
Suitable "lower alkyl" and "lower alkyl moiety" in the terms "indolyl(lower)alkyl" and "lower alkylsulfonyl" is straight or branched one having 1 to 6 carbon atom(s) and may include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, hexyl and the like.
Suitable "trihalo (lower) alkyl" may include trichloromethyl, tribromomethyl, trifluoromethyl and the like. Suitable "lower alkoxy" and "lower alkoxy moiety" in the terms "lower alkoxycarbonyl" and "lower alkoxy(lower)alkanoyl" may include methoxy, ethoxy, isopropyloxy, butoxy and the like.
Suitable "lower alkanoyl" and "lower alkanoyl moiety" in the term "lower alkoxy(lower)alkanoyl" may include formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, hexanoyl, pivaloyl and the like.
Suitable "cyclo (lower)alkyl moiety" in the term "cyclo(lower) alkylcarbonyl" may include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.
Suitable "aroyl" may include benzoyl, toluoyl, naphthoyl and the like.
Suitable "leaving group" may include hydroxy, reactive group derived from hydroxy and the like. Suitable "reactive group derived from hydroxy" may include acid residue and the like.
Suitable "acid residue" may include halogen (e.g. fluoro, chloro, bromo, iodo) , acyloxy (e.g. acetoxy, tosyloxy, mesyloxy, etc.) and the like.
The Processes 1 to 4 for preparing the object compounds of the present invention are explained in detail in the following.
Process 1
The object compound (I) or a salt thereof can be prepared by reacting a compound (II) or its reactive derivative at the carboxy group or a salt thereof with a compound (III) or its reactive derivative at the amino group or a salt thereof.
Suitable reactive derivative at the carboxy group of the compound (II) may include an acid halide, an acid anhydride, an activated amide, an activated ester, and the like. Suitable examples of the reactive derivatives may be an acid chloride; an acid azide; a mixed acid anhydride with an acid such as substituted phosphoric acid [e.g. dialkylphosphoric acid, phenylphosphoric acid, diphenylphosphoric acid, dibenzylphosphoric acid, halogenated phosphoric acid, etc.], dialkylphosphorous acid, sulfurous acid, thiosulfuric acid, sulfuric acid, sulfonic acid [e.g. methanesulfonic acid, etc.], aliphatic carboxylic acid [e.g. acetic acid, propionic acid, butyric acid, isobutyric acid, pivalic acid, pentanoic acid, isopentanoic acid,
2-ethylbutyric acid, trichloroacetic acid, etc.] or aromatic carboxylic acid [e.g. benzoic acid, etc.]; a symmetrical acid anhydride; an activated amide with imidazole, 4-substituted imidazole, di ethylpyrazole, triazole or tetrazole; or an activated ester [e.g. cvanomethyl ester, methoxymethyl ester, dimethyliminomethyl [ ester, vinyl ester, propargyl ester, p-nitrophenyl ester, 2,4-dinitrophenyl ester, trichlorophenyl ester, pentachlorophenyl ester, mesylphenyl ester, phenylazophenyl ester, phenyl thioester, p-nitrophenyl thioester, p-cresyl thioester, carboxymethyl thioester, pyranyl ester, pyridyl ester, piperidyl ester, 8-quinolyl thioester, etc.], or an ester with a N-hydroxy compound [e.g. N,N-dimethylhydroxylamine, l-hydroxy-2- (1H)- pyridone, N-hydroxysuccinimide, N-hydroxyphthalimide, 1-hydroxy-lH-benzotriazole, etc.], and the like. These reactive derivatives can optionally be selected from the above according to the kind of the compound (II) to be used. Suitable reactive derivative at the amino group of the compound (III) may include Schiff's base type imino or its tautomeric enamine type isomer formed by the reaction of the compound (III) with a carbonyl compound such as aldehyde, ketone or the like; a silyl derivative formed by the reaction of the compound (III) with a silyl compound such as bis (trimethylsilyl)acetamide, mono (trimethylsilyl) acetamide, bis (trimethylsilyl)urea or the like; a derivative formed by reaction of the compound (III) with phosphorus trichloride or phosgene and the like.
The reaction is usually carried out in a conventional solvent such as water, alcohol [e.g. methanol, ethanol, etc.], acetone, 2-butanone, dioxane, acetonitrile, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, pyridine or any other organic solvent which does not adversely influence the reaction, or the mixture thereof. In this reaction, when the compound (II) is used in a free acid form or its salt form, the reaction is preferably carried out in the presence of a conventional condensing agent such as N,N'-dicyclohexylcarbodiimide; N-cyclohexyl-N'-morpholinoethylcarbodiimide; N-cyclohexyl-N'- (4-diethylaminocyclohexyl) carbodiimide; N,N'-diethylcarbodiimide; N,N'-diisopropylcarbodiimide; N-ethyl-N'- (3-dimethylaminopropyl)carbodiimide; pentamethyleneketene-N-cyclohexylimine; diphenylketene-N-cyclohexylimine; ethoxyacetylene; 1-alkoxy-l-chloroethylene; trialkyl phosphite; ethyl polyphosphate; isopropyl polyphosphate; phosphorus oxychloride (phosphoryl chloride) ; phosphorus trichloride; diphenyl phosphorylazide; thionyl chloride; oxalyl chloride; lower alkyl haloformate [e.g. ethyl chloroformate, isopropyl chloroformate, etc.]; triphenylphosphine; 2-ethyl-7-hydroxybenzisoxazolium salt; 2-ethyl-5- (m-sulfophenyl) isoxazolium hydroxide intramolecular salt; 1- (p-chlorobenzenesulfonyloxy)-6-chloro-lH- benzotriazole; 1-hydroxybenzotriazole; so-called Mukaiyama reagent such as 2-chloro-l-methylpyridinium iodide;
1- (3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride by itself or in combination with 1-hydroxybenzotriazole; so called Vilsmeier reagent prepared by the reaction of N,N-dimethylformamide with thionyl chloride, phosgene, trichloromethyl chloroformate, phosphorus oxychloride, etc.; or the like, or the mixture thereof.
The reaction may also be carried out in the presence of an inorganic or organic base such as an alkali metal bicarbonate, tri (lower)alkylamine, pyridine, N-(lower) alkylmorpholine, N,N-di (lower)alkylbenzylamine, or the like.
The reaction temperature is not critical, and the reaction is usually carried out under cooling to warming.
Process 2
The object compound (If) can be prepared by reacting the compound (I) or a salt thereof other than fumaric acid salt thereof with fumaric acid.
The reaction is usually carried out in a conventional solvent such as water, alcohol [e.g. methanol, ethanol, etc.], acetone, 2-butanone, dioxane, acetonitrile, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, pyridine or any other organic solvent which does not adversely influence the reaction, or the mixture thereof. The reaction temperature is not critical, and the reaction is usually carried out under cooling to warming.
Process 3 The object compound (Ig') or a salt thereof can be prepared by reacting the compound (IV) or its reactive derivative at the imino group or a salt thereof with the compound (V) or a salt thereof.
Suitable reactive derivative at the imino group of the compound (IV) may include Schiff's base type imino or its tautomeric enamine type isomer formed by the reaction of the compound (IV) with a carbonyl compound such as aldehyde, ketone or the like; a silyl derivative formed by the reaction of the compound (IV) with a silyl compound such as bis (trimethylsilyl) acetamide, mono(trimethylsilyl)acetamide. bis (trimethylsilyl)urea or the like; a derivative formed by reaction of the compound (IV) with phosphorus trichloride or phosgene and the like.
This reaction is usually carried out in a solvent such as alcohol [e.g. methanol, ethanol, etc.], dichloromethane, benzene, N,N-dimethylformamide, tetrahydrofuran, diethyl ether or any other solvent which does not adversely affect the reaction.
The raction may be carried out in the presence of an inorganic or an organic base such as an alkali metal hydroxide [e.g. sodium hydroxide, potassium hydroxide, etc.], an alkali metal carbonate [e.g. sodium carbonate, potassium carbonate, etc.], an alkali metal bicarbonate [e.g. sodium bicarbonate, potassium bicarbonate, etc.], alkali metal hydride [e.g. sodium hydride, potassium hydride, etc.], tri (lower) alkylamine [e.g. trimethylamine, triethylamine, diisopropylethylamine, etc.], pyridine or its derivative [e.g. picoline, lutidine, 4-dimethylaminopyridine, etc.], or the like. In case that the base to be used in liquid, it can also be used as a solvent.
The reaction temperature is not critical, and the reaction can be carried out under cooling, at room temperature or under warming or heating.
Process 4
The compound (Ig") or a salt thereof can be prepared by reacting a compound (IV) or its reactive derivative at the imino group or a salt thereof with a compound (VI) or its reactive derivative at the carboxy group or a salt thereof. The reaction can be carried out in the manner disclosed in Preparation 10 or similar manners thereto.
The object compounds of the present invention have pharmacological activities such as Tachykinin antagonism, especially Substance P antagonism, Neurokinin A antagonism or Neurokinin B antagonism, and therefore are useful for treating or preventing Tachykinin-mediated diseases, particularly Substance P-mediated diseases, for example, respiratory diseases such as asthma, bronchitis (e.g. chronic bronchitis, acute bronchitis and diffuse panbronchiolitis, etc.), rhinitis, cough, expectoration, and the like; ophthalmic diseases such as conjunctivitis, vernal conjunctivitis, and the like; cutaneous diseases such as contact dermatitis, atopic dermatitis, urticaria, and other eczematoid dermatitis, and the like; inflammatory diseases such as rheumatoid arthritis, osteoarthritis, and the like; pains or aches (e.g. migraine, headache, cluster headache, toothache, cancerous pain, back pain, neuralgia, etc.); and the like.
Further, it is expected that the object compounds of the present invention are useful for treating or preventing ophthalmic diseases such as glaucoma, uveitis, and the like; gastrointestinal diseases such as ulcer, ulcerative colitis, irritable bowel syndrome, food allergy, and the like; inflammatory diseases such as nephritis, and the like, circulatory diseases such as hypertension, angina pectoris, cardiac failure, thrombosis, Raynaud's disease, and the like; epilepsy; spastic paralysis; pollakiuria; cystitis; bladder detrusor hyperreflexia; urinary incontinence; Parkinson- diseases; dementia; AIDS related dementia; Alzheimer's diseases; Down's syndrome; Huntington's chorea; carcinoid syndrome; disorders related to immune enhancement or suppression; disorders caused by Helicobacter pylori or another spiral urease-positive gram-negative bacterium; sunburn; angiogenesis or diseases caused by angiogenesis; and the like.
It is furthermore expected that the object compounds of the present invention are useful for treating or preventing chronic obstructive pulmonary diseases, particularly chronic pulmonary emphysema; iritis; proliferative vitreoretinopathy; psoriasis; inflammatory intestinal diseases, particularly Crohn's diseases; hepatitis; superficial pain on congelation, burn, herpes zoster or diabetic neuropathy; tenalgia attended to hyperlipidemia; postoperative neuroma, particularly of mastectomy; vulvar vestibulitis; he odialysis-associated itching; lichen planus; laryngopharyngitis; bronchiectasis; coniosis; whooping cough; pulmonary tuberculosis; cystic fibrosis; e esis; mental diseases, particularly anxiety, depression, dysthymic disorders and schizophrenia; demyelinating diseases such as multiple sclerosis and amyotrophic lateral sclerosis; attenuation of morphine withdrawal; oedema, such as oedema caused by thermal injury; small cell carcinomas, particularly small cell lung cancer (SCLC) ; hypersensitivity disorders such as poison ivy; fibrosing and collagen diseases such as scleroderma and eosinophilic fascioliasis; reflex sympathetic dystrophy such as shoulder/hand syndrome; addiction disorders such as alcoholism; stress related somatic disorders; rheumatic diseases such as fibrositis; and the like.
For therapeutic purpose, the object compounds of the present invention can be used in a form of pharmaceutical preparation containing one of said compound, as an active ingredient, in admixture with a pharmaceutically acceptable carrier such as an organic or inorganic solid or liquid excipient suitable for oral, parenteral, external including topical, enteral, intravenous, intramuscular, inhalant, nasal, intraarticular, intraspinal, transtracheal or transocular administration. The pharmaceutical preparations may be solid, semi-solid or solutions such as capsules, tablets, pellets, dragees, powders, granules, suppositories, ointments, creams, lotions, inhalants, injections, cataplasms, gels, tapes, eye drops, solution, syrups, aerosols, suspension, emulsion, or the like. If desired, there may be included in these preparations, auxiliary substances, stabilizing agents, wetting or emulsifying agents, buffers and other commonly used additives.
While the dosage of the object compounds will vary depending upon the age and condition of a patient, an average single dose of about 0.1 mg, 1 mg, 10 mg, 50 mg, 100 mg, 250 mg, 500 mg and 1000 mg of the object compounds may be effective for treating Tachykinin-mediated diseases such as asthma and the like. In general, amounts between 0.1 mg/body and about 1,000 mg/body may be administered per day.
In order to illustrate the usefulness of the object compounds, the pharmacological test data of a representative compound of the present invention is shown in the following.
The following Test Compound showed more than 90%
-I OC inhibition rate of ± I-BH-Substance P binding to h-NK-*_ receptors at the concentration of 0.1 μg/ml.
Test. Compound : The object compound of the Example 2
-2A-BH-Substance P Binding to h-NK-*_ Receptors
Test Method : 125I-BH-Substance P Binding to h-NK Receptors
(a) Crude CHO cell membrane preparation
CHO cells permanently expressing h-NK-, receptors were harvested and homogenized with a Dounce homogenizer at 4°C in a buffer (0.25 M sucrose, 25 M Tris-HCl pH 7.4, 10 mM MgCl2,
1 mM EDTA, 5 μg/ml p-APMSF) . The homogenate was centrifuged (500 x g, 10 minutes) , and the pellet was resuspended in the same buffer, homogenized, and centrifuged. The two supernatants were combined and centrifuged (100,000 x g, I hour) . The crude cell membranes thus isolated were resuspended in buffer (25 mM Tris-HCl pH 7.4, 10 mM MgCl2, 1 mM EDTA, 5 μg/ml p-APMSF) and stored at -80°C until use.
(b) ^-2A-BH-Substance p binding to preparation membrane
Cell membranes (6 μg/ml) were incubated with 12^I-BH- Substance P (0.1 nM) with or without test compounds in 0.25 ml of Medium 2 (50 mM Tris-HCl pH 7.4, 5 mM MnCl2, 20 μg/ml chvmostatin, 40 μg/ml bacitracin, 4 μg/ml leupeptin, 5 μg/ml p-APMSF, 200 μg/ml BSA) at 22°C for 90 minutes. At the end of the incubation period, the content was quickly filtered over a Wahtman GF/C glass filter (pretreated with 0.1% polyethylene imine for 3 hours prior to use) under aspiration. Each of the filters was then washed four times with 5 ml of buffer (50 mM Tris-HCl pH 7.4, 5 mM MnCl2) . The radioactivity was counted by using Auto Gamma counter (Packerd RIASTAR 5420A) . All data presented are specific binding defined as that displaceable by 3 μM unlabeled Substance P.
Further, the object compound of the present invention, especially the compound (If), is also superior in stability and the like.
EXAMPLES The following Preparations and Examples are given for the purpose of illustrating the present invention in more detail.
- to be continued on the next page - Preparation 1
To a mixture of N^-(tert-butoxycarbonyl)-Nx-formyl-D- tryptophan (3.99 g) and N-benzyl glycin benzyl ester hydrochloride (3.50 g) in dichloromethane (70 ml) was added triethylamine (5.85 ml) under nitrogen atmosphere. To the mixture was added 2-chloro-l-methylpyridinium iodide (3.67 g) at room temperature, and the resulting mixture was stirred for 2 hours. After the reaction was completed, dichloromethane (30 ml) and water (30 ml) were added. The organic layer was separated, washed with 0.5N hydrochloric acid (10 ml), water (10 ml), aqueous sodium bicarbonate solution (10 ml) and brine (20 ml) successively and dried over magnesium sulfate. After evaporation of the solvent, the residue was purified on a silica gel column (140 g) eluting with a mixture of toluene and ethyl acetate (4:1) to give (2R)-N-benzyl-N-benzyloxycarbonylmethyl-2- (tert- butoxycarbonylamino)-3- (N-formyl-lH-indol-3-yl)propanamide (6.41 g) as an oil. IR (CHCI3) : 3300, 2970, 1740, 1700, 1644, 1604 cm"1 NMR (DMSO-d6, δ) : 0.89, 1.22 and 1.29 (9H, 3 s) ;
2.80-3.10 (2H, m) ; 3.95-4.25 (2H, ) ; 4.40-4.90
(3H, m) ; 4.95-5.20 (2H, m) ; 7.05-7.75 (15H, m) ;
7.98 and 8.22 (1H, 2 br s) ; 9.22 and 9.61 (1H, 2 br s) MASS : 570 (M+l)
Preparation 2
To an ice-cooled solution of the object compound of Preparation 1 (6.39 g) in dichloromethane (50 ml) was added 4N hydrogen chloride in dioxane solution (50 ml) . The mixture was stirred at the same temperature for 30 minutes and at room temperature for 1 hour. After evaporation of the solvent, the residue was partitioned between dichloromethane (50 ml) and aqueous sodium bicarbonate solution (30 ml) . The organic layer was separated, dried over magnesium sulfate and filtered. To the filtrate was added triethylamine (1.67 ml) at room temperature, and the mixture was stirred for 1.5 hours. After evaporation, the residue was triturated with diisopropyl ether, collected by filtration and dried to give (3R)-l-benzyl-3- (N-formyl-lH-indol-3-ylmethyl)piperazine-2,5- dione (3.93 g) . mp : 176-178°C
IR (Nujol) : 3250, 1709, 1648, 1630 cm-1 NMR (DMSO-d6, δ) : 2.95-3.30 and 3.35-3.70 (4H, 2 m) 4.22 (1H, d, J=14.6Hz); 4.30-4.40 (1H, m) ; 4.54 (1H, d, J=14.9Hz); 6.80-7.75 (9H, ) ; 7.95-8.50 (2H, m) ; 9.20 and 9.65 (1H, 2 br s)
Preparation 3
To an ice-cooled solution of the object compound of
Preparation 2 (3.89 g) in a mixture of methanol (175 ml) and tetrahydrofuran (50 ml) was added aqueous 0.IN sodium hydroxide solution (108 ml) . The mixture was stirred at the same temperature for 30 minutes and at room temperature for 1.5 hours. After evaporation of the solvent, the residue was extracted with dichloromethane. The organic layer was washed with water and an aqueous sodium chloride solution, and dried over magnesium sulfate. Evaporation of the solvent gave (3R)-l-benzyl-3- (lH-indol-3-ylmethyl)piperazine-2,5-dione (3.68 g) . mp : 207-208°C
IR (Nujol) : 3402, 1650 cm-1
NMR (DMSO-d6, δ) : 2.68 (1H, d, J=17.2Hz); 3.04 (1H, dd, J=14.4 and 4.4Hz); 3.20-3.40 (2H, ) ; 4.24 (1H, s); 4.10-4.40 (2H, ) ; 6.75-7.60 (10H, m) ; 8.35 (1H, s); 10.94 (1H, s) MASS : 334 (M+l)
Preparation 4
To a suspension of lithium aluminum hydride (0.77 g) in tetrahydrofuran (40 ml) was added dropwise a solution of the object compound of Preparation 3 (3.40 g) in tetrahydrofuran (40 ml) at 0°C under nitrogen atmosphere. The mixture was stirred at room temperature for 50 minutes and at refluxing temperature for 1 hour. The resulting mixture was diluted with tetrahydrofuran (60 ml) and cooled to 0°C. Water (3.0 ml) and aqueous 15% sodium hydroxide solution (0.8 ml) were added slowly. The resulting insoluble inorganic material was removed by filtration and washed with tetrahydrofuran. The filtrate and the washing were combined and evaporated under reduced pressure to give (3R) -l-benzyl-3- (lH-indol-3- ylmethyl)piperazine (3.68 g) as an oil.
IR (CHC13) : 3240, 3040, 2900 cm-1
NMR (DMSO-dβ, δ) : 1.70-2.00 and 2.30-2.45 (2H, 2 m) ; 2.50-3.00 (7K, m) ; 3.25-3.60 (3H, ) ; 6.80-7.60 (10H, m) ; 10.80 (1H, s)
MASS : 306 (M+l) - 20 -
Preparation 5
To a mixture of 3, 5-bis (trifluoromethyl)benzoic acid (1.15 g) and (3R) -l-benzyl-3- (lH-indol-3-ylmethyl)piperazine (1.61 g) in dichloromethane (80 ml) was added triethylamine (1.55 ml) at room temperature under nitrogen atmosphere. 2-Chloro-l-methylpyridinium iodide (1.37 g) was added, and the mixture was stirred at room temperature for 2.5 hours. The resulting mixture was poured into water (20 ml) . The organic layer was washed successively with 0.5N hydrochloric acid, water, aqueous sodium bicarbonate solution and brine, and dried over magnesium sulfate. After evaporation under reduced pressure, the residue was chromatographed on silica gel with toluene - ethyl acetate (4:1) as an eluent to give (2R) -4-benzyl-l- [3, 5-bis (trifluoromethyl)benzoyl] -2- (1H- indol-3-ylmethyl)piperazine (0.87 g) as a syrup. IR (CHC13) : 3430, 3300, 3000, 2910, 2800,
1630-1610 cm-1 NMR (DMSO-d6, δ) : 1.90-2.40 (2H, m) ; 2.70-3.90 (8H, m) ; 4.25-4.40 and 4.75-4.90 (1H, m) ; 6.50-7.45 (10H, m) ; 7.50-8.25 (3H, m) ; 10.77 (1H, s) MASS : 546 (M+l) Preparation 6
A mixture of (2R)-4-benzyl-l-[3,5-bis (trifluoromethyl) - benzoyl]-2- (lH-indol-3-ylmethyl)piperazine (5.20 g) , ammonium formate (1.50 g) and 10% Pd charcoal (0.52 g) in ethanol (50 ml) was refluxed for 7.5 hours under nitrogen atmosphere. The reaction mixture was cooled to room temperature and filtered through Celite pad. The filtrate was concentrated under reduced pressure and the residue was purified on a silica gel column eluting with a mixture of dichloromethane and methanol (20:1) to give (2R)-1-[3,5-bis (trifluoromethyl)- benzoyl]-2- (lH-indol-3-ylmethyl)piperazine (2.67 g) as a syrup.
IR (CHC13) : 3280, 2900, 1622 cm-1 NMR (DMSO-d6, δ) : 2.50-3.50 (9H, m) ; 3.6-4.8 (1H, m) ;
6.55-7.40 (5H, m) ; 7.50-8.22 (3H, m) ; 10.84 (1H, s) MASS : 456 (M+l)
Preparation 7
A mixture of (2R)-1-[3,5-bis (trifluoromethyl)benzoyl] -2- (lH-indol-3-ylmethyl)piperazine (1.5 g) , benzyl 2-bromoacetate (0.79 g) , triethylamine (0.55 ml) and tetrahydrofuran (15 ml) was stirred overnight at room temperature. The resulting insoluble material was removed by filtration and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel eluting with a mixture of dichloromethane and methanol (30:1) to give (2R)-4- (benzyloxycarbonylmethyl)-1- [3, 5-bis (trifluoromethyl)benzoyl]-2- (lH-indol-3-ylmethyl)- piperazine (1.92 g) .
[α]^1 : -11.6° (C=1.0, MeOH)
IR (Neat) : 3600-3100, 1735, 1626, 1275, 1129, 900 cm-1 NMR (DMSO-d6, δ) : 2.20-5.20 (13H, m) ; 6.60-8.20 (13H, m) ; 10.85 (1H, br s) MASS : 604 (M+l), 454
Preparation 8
A mixture of (2R)-4-(benzyloxycarbonylmethyl)-1-[3,5- bis (trifluoromethyl)benzoyl]-2- (lH-indol-3-ylmethyl) - piperazine (1.86 g) , 10% Pd charcoal (0.186 g) and tetrahydrofuran (93 ml) was stirred for 17 hours under hydrogen gas atmosphere (1 atm) . The catalyst was removed by filtration and the filtrate was concentrated. The residue was triturated with ethyl ether to give (2R)-4- (carboxymethyl) -1-[3,5-bis (trifluoromethyl)benzoyl]-2- (1H- indol-3-ylmethyl)piperazine (0.83 g) as a white powder. mp : 152-156°C
IR (Nujol) : 3600-3100, 1654, 1630, 1277, 1196, 1130 cm-1
NMR (DMSO-d6, δ) : 2.20-5.20 (11H, m) ; 6.60-8.20 (8H, m) ; 10.85 (1H, s) MASS : 514 (M+l)
Preparation 9
To an ice-cooled mixture of (2R)-2-benzyl-l-[3,5- bis (trifluoromethyl)benzoyl]piperazine (0.3 g) and triethylamine (0.39 ml) in dimethylformamide (8 ml) was added 3-(chloromethyl)pyridine hydrochloride (0.12 g) . The reaction mixture was stirred at the same temperature for 30 minutes and then at room temperature for 2 hours. Additional triethylamine (0.39 ml) and 3- (chloromethyl)pyridine hydrochloride (0.12 g) were added and the resulting mixture was stirred overnight. The reaction mixture was filtered and the filtrate was concentrated and subjected to a chromatography on a silica gel eluting with a mixture of toluene and ethyl acetate (5:1) . The eluent was treated with 4N hydrogen chloride in ethyl acetate solution to give (2R)- 2-benzyl-l- [3, 5-bis (trifluoromethyl)benzoyl]-4- (pyridin-3-yl- methyl)piperazine dihydrochloride. mp : 164-168°C
[α]§5 +9.1° (C=1.0, MeOH) IR (Nujol) : 3700-3100, 2700-2000, 1630, 1270, 1120,
900 cm-1 NMR (DMSO-d6, δ) : 2.80-5.40 (11H, m) ; 6.85-6.90 (1H, m) ; 7.10-7.40 (4H, m) ; 7.46 (1H, s) ; 7.75 (1H, s) ; 7.90-8.00 (1H, m) ; 8.19-8.23 (1H, m) ; 8.66-8.70 (1H, m) ; 8.88-8.91 (1H, m) ; 9.09 (1H, s) MASS : 508 (M+l) (free)
Preparation 10
To a stirred mixture of (2R)-2-benzyl-l-[3,5- bis (trifluoromethyl)benzoyl]piperazine (0.3 g) and 2-(lH- indol-3-yl)acetic acid (0.13 g) in dichloromethane (8 ml) containing triethylamine (0.25 ml) was added 2-chloro-l- methylpyridinium iodide (0.22 g) at room temperature under nitrogen atmosphere. After being stirred for 5 hours, the reaction mixture was diluted with dichloromethane and washed with 0.1N hydrochloric acid, aqueous saturated sodium bicarbonate solution and brine, and dried over magnesium sulfate. After removal of the solvent, the residue was purified by column chromatography on silica gel using chloroform-methanol (50:1) as eluent to give (2R)-2-benzyl-l- [3, 5-bis (trifluoromethyl)benzoyl]-4-[2- (lH-indol-3- yl)acetyl]piperazine (0.34 g) as a white powder. p : 201-210°C
[α]§7 : +27.6° (C=1.0, MeOH)
IR (Nujol) : 3270, 1630, 1276, 1115, 900, 737 cm-1 NMR (DMSO-d6, δ) : 2.60-5.00 (11H, ) ; 6.70-7.70 (12H, ) ; 8.10-8.20 (1H, ) ; 10.85-11.10 (1H, m) MASS : 574 (M+l), 417
Preparation 11
To a solution of (2R)-1-[3,5-bis (trifluoromethyl)- benzoyl]-2- (lH-indol-3-ylmethyl)piperazine (0.1 g) in dichloromethane (10 ml) was added 4N hydrogen chloride in dioxane solution (0.05 ml) at 0°C. The resulting mixture was stirred at the same temperature for 50 minutes and then concentrated under reduced pressure. The obtained powder was collected by filtration and washed with ethyl ether to give (2R)-1-[3,5-bis (trifluoromethyl)benzoyl]-2- (lH-indol-3- ylmethyl)piperazine hydrochloride (0.1 g) . IR (Nujol) : 3340, 1648 cm"1
NMR (DMSO-d6, δ) : 2.9-3.9 (8H, m) ; 3.9-5.2 (1H, ) ; 6.57-7.50 (5H, ) ; 7.50-8.30 (3H, m) ; 9.40-10.00 (2H, ) ; 10.96 (1H, s) MASS : 456 (M+l ) ( free )
Preparation 12
To a stirred mixture of (2R) -4- (2-aminoethyl)-1-[3,5- bis (trifluoromethyl)benzoyl]-2- (3, -dimethylbenzyl)piperazine dihydrochloride (110 mg) , triethylamine (0.2 ml) in dichloromethane (10 ml) was added methanesulfonyl chloride (0.1 ml) at 0°C. After stirring for 1 hour, the reaction mixture was poured into ice-water and extracted with ethyl acetate. The extract was washed successively with aqueous saturated sodium bicarbonate solution and brine, and dried. After evaporation of the solvent in vacuo, the residue was purified by column chromatography on a silica gel eluting with a mixture of dichloromethane and methanol (40:1) and treated with 4N hydrogen chloride in ethyl acetate solution to give (2R)-1-[3,5-bis (trifluoromethyl)benzoyl]-2- (3, 4- dimethylbenzyl)-4-[2- (mesylamino)ethyl]piperazine hydrochloride (50 mg) . mp : >220°C [α]§2 : +0.2° (C=0.5, DMF)
IR (Nujol) : 3350, 2700-2400, 1645, 1500, 1450,
1380 cm-1 NMR (DMSO-d6, δ) : 2.10 and 2.18 (6H, 2 s) ; 2.7-5.2
(17H, ) ; 6.6-7.7 (5H, ) ; 8.1-8.2 (1H, m) ; 11.05- 11.4 (1H, m)
MASS : 566 (M+l) (free)
Example 1
To a stirred solution of (2R)-4- (carboxymethyl)-1-[3,5- bis (trifluoromethyl)benzoyl]-2- (lH-indol-3-ylmethyl)- piperazine (1 g) in dry dimethylformamide (10 ml) was added
1-hydroxybenzotriazole (0.29 g) and l-(3- dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.41 g) at room temperature. After stirring for 15 minutes at room temperature, l-amino-4-methylpiperazine (320 mg) was added and further stirred for 5 hours at the same temperature. The reaction mixture was poured into a solution of sodium hydrogencarbonate (1.8 g) in water (100 ml) and extracted three times with 20 ml portions of ethyl acetate. The organic layers were combined and washed with brine (30 ml) . The organic layer was dried over magnesium sulfate and filtered and the solvent was removed by rotary evaporator. The crude product was purified by chromatography (silica gel, dichloromethane:methanol, 5:1) to afford (2R) -1-[3,5-bis (trifluoromethyl)benzoyl]-2- (lH-indol-3- ylmethyl)-4- [N- (4-methyl-l-piperazinyl)carbamoylmethyl]- piperazine (0.94 g) as a yellowish powder.
IR (Nujol) : 3180, 1680, 1630, 1276, 1170, 1130, 1005, 897 cm"1 NMR (DMSO-d6, δ) : 2.16 (3H, s) ; 2.0-5.0 (19H, m) ;
6.6-8.2 (8H, m) ; 8.47, 8.77 (1H, 2 s) ; 10.85 (1H, s)
Example 2 (2R)-l-[3,5-Bis (trifluoromethyl)benzoyl]-2- (lH-indol-3- ylmethyl) -4-[N- (4-methyl-l-piperazinyl) carbamoylmethyl]- piperazine (10.89 g) and fumaric acid (2.07 g) were dissolved in ethanol (50 ml) at 70°C. After cooling, the resulting solution was concentrated under reduced pressure to give a powder (13.18 g) . The powder (9.68 g) was dissolved in
2-butanone (194 ml) at reflux temperature and the solution was allowed to stir at room temperature to afford crystals, which was collected by filtration and dried to give (2R)-1- [3,5-bis (trifluoromethyl)benzoyl]-2- (lH-indol-3-ylmethyl)-4- [N- (4-methyl-l-piperazinyl)carbamoylmethyl]piperazine fumarate (7.94 g) . mp : 169.5-171°C
IR (Nujol) : 3220, 1700, 1653, 1630, 1275, 1217, 1168, 1122, 979, 894, 730 cm"1 NMR (DMSO-d6, δ) : 2.23, 2.26 (3H, 2 s) ; 2.10-4.93 (19H, m) ; 6.60 (2H, s) ; 6.54-8.23 (8H, m) ; 8.50, 8.85 (1H, 2 s) ; 10.85 (1H, s)
Example 3
Compound τ (If) , namely (2R) -1- [3, 5-bis (trifluoromethyl) benzoyl] -2- (lH-indol-3-ylmethyl) -4- [N- (4-methyl-l- piperazinyl) carbamoylmethyl]piperazine fumarate was also obtained according to the following scheme.
IΠD 224-225 C (dec)
t) 243 C (dec) LiAlH4
BrCH2C02C2H5
ITID 152-156 C
Compound (I)
Compound (If; Example 4
A mixture of (2R)-1-[3,5-bis(trifluoromethyl)benzoyl]-2- (lH-indol-3-ylmethyl)piperazine (120 mg) , 4-chloromethyl-2- (2-methoxyethylcarbonylamino)thiazole (70 mg) and powdered sodium hydrogen carbonate (27 mg) in dry dimethylformamide was stirred for 5 hours and 20 minutes at 60CC. The reaction mixture was powered into water and the resulting precipitate was collected by filtration. The crude product was purified by column chromatography on silica gel eluting with a mixture of dichloromethane and methanol (30:1). The eluate was evaporated under reduced pressure and treated with 17.6% hydrogen chloride in ethanol (0.12 ml) to give (2R)-1-[3,5- bis (trifluoromethyl)benzoyl]-2- (lH-indol-3-ylmethyl)-4-[ [2- (3-methoxypropanoylamino)thiazol-4-yl]methyl]piperazine hydrochloride (140 mg) .
[α]g2 : -34.0° (C=0.5, MeOH)
IR (Nujol) : 3650-3100, 2750-2000, 1635, 1275, 1130, 900 cm-1
NMR (DMSO-d6, δ) : 2.60-5.20 (18H, ) ; 6.60-8.21 (9H, ) ; 10.90-11.00 (1H, m) ; 11.20-12.00 (1H, ) ; 12.19 (1H, s)
MASS : 654 (M+l) (free)
Example 5 The following piperazine derivatives (Table 1) were prepared by the similar manner to that of the each Example
No. or Preparation No. defined in the "Process" column. The physical properties of the object compounds are shown after the table.
Table 1
-
Table 1 (continued)
Physical properties of the compounds of the Example 5
Example 5-1) mp : 185-189°C
[α]§4 : 30.2° (C=0.5, MeOH)
IR (Nujol) : 3660-3100, 2800-2000, 1635, 1545, 1276,
1183, 1130, 900 cm"1 NMR (DMS0-d6, δ) : 1.36-5.10 (14H, m) ; 6.59-8.22 (10H, m) ; 10.90-11.00 (1H, m) ; 12.15 (1H, s) MASS : 610 (M+l) (free), 456
Example 5-2)
[α]g2 : -33.4° (C=0.5, MeOH)
IR (Nujol) : 3650-3100, 2800-2000, 1715, 1635, 1555,
1274, 1130, 900 cm"1 NMR (DMSO-d6, δ) : 1.25 (3H, t, J=7.1Hz); 2.73-5.10
(13H, m) ; 6.60-8.30 (9H, ) ; 10.90-11.00 (1H, ) ; 11.81 (1H, br s) MASS : 640 (M+l) (free), 456
Example 5-3)
[α]§2 : -42.0° (C=0.5, MeOH)
IR (Nujol) : 3600-3100, 2750-2000, 1635, 1540, 1277, 1175, 1130 cm"1 NMR (DMSO-d6, δ) : 2.73-5.20 (11H, m) ; 6.59-8.21 (14H, m) ; 10.90-11.00 (IH, m) ; 12.69 (IH, s) MASS : 672 (M+l) (free), 456
Example 5-4)
[α]g2 : -24.2° (C=0.5, MeOH)
IR (Nujol) : 3650-3100, 2750-2000, 1635, 1540, 1276, 1170, 1129, 900 cm"1 NMR (DMSO-d6, δ) : 1.23 (9H, s) ; 2.73-5.10 (11H, m) ;
6.50-8.20 (9H, ) ; 10.80-11.00 (IH, ) ; 11.84 (IH, s) MASS : 652 (M+l) (free), 456
Example 5-5)
[α]2 ) 2 : -35.8° (C=0.5, MeOH)
IR (Nujol) : 3650-3100, 2750-2000, 1635, 1540, 1276,
1170, 1130, 900 cm"1 NMR (DMSO-d6, δ) : 0.80-1.00 (4H, ) ; 1.90-2.00 (IH, m) ; 2.73-5.15 (11H, m) ; 6.60-8.21 (9H, ) ; 10.90-
11.00 (IH, m) ; 12.43 (IH, ) MASS : 636 (M+l) (free), 456
Example 5-6) [α]§2 : -30.4° (C=0.5, MeOH)
IR (Nujol) : 3650-3100, 2750-2000, 1635, 1542, 1275,
1170, 1131, 900 cm"1 NMR (DMSO-d6, δ) : 0.89 (3H, t, J=7.4Hz); 1.56-1.67 (2H, m) ; 2.40-2.50 (2H, m) ; 2.73-5.15 (11H, m) ; 6.56-8.21 (9H, m) ; 10.90-10.94 (IH, m) ; 12.12 (IH, s) MASS : 638 (M+l) (free)
Example 5-7) [α]g2 : -34.0° (C=0.5, MeOH) IR (Nujol) : 3650-3100, 2750-2000, 1635, 1543, 1277,
1170, 1130, 900 cm"1 NMR (DMSO-d6, δ) : 1.08 (3H, t, J=7.4Hz); 2.43-2.50 (2H, m) ; 2.73-5.15 (11H, m) ; 6.55-8.21 (9H, m) ; 10.90-10.94 (IH, m) ; 12.11 (IH, s)
MASS : 624 (M+l) (free)
Example 5-8)
[α]2 ) 2 : -15.2° (C=0.5, MeOH) IR (Nujol) : 3600-3100, 2750-2000, 1635, 1278, 1172,
1130, 900 cm"1 NMR (DMSO-d6, δ) : 2.73-5.20 (11H, m) ; 6.60-8.52 (11H, m) ; 10.94 (IH, s) MASS : 596 (M+l) (free), 456
Example 5-91
[α]§2 : -20.6° (C=0.5, MeOH)
IR (Nujol) : 3650-3100, 2750-2000, 1635, 1276, 1170, 1129, 900 cm"1 NMR (DMSO-d6, δ) : 2.09 (3H, s) ; 2.73-5.20 (11H, ) ;
6.60-8.20 (11H, m) ; 10.46 (IH, s) ; 10.91 (IH, s) MASS : 604 (M+l) (free)
Example 5-10) [α]g2 : -13.0° (C=0.5, MeOH)
IR (Nujol) : 3650-3050, 2750-2000, 1685, 1636, 1524,
1275, 1130, 900 cm"1 NMR (DMSO-d6, δ) : 1.31 (3H, t, J=6.5Hz); 2.24 (3H, s); 2.73-5.20 (13H, ) ; 6.66-8.25 (8H, ) ; 10.94 (IH, s), 12.71 (IH, s)
MASS : 682 (M+l) (free)
Example 5-11)
[α]J8 : -20.8° (C=0.5, MeOH) IR (Neat) : 3700-3000, 1615, 1515, 1272, 1125,
NMR (DMSO-dβ, δ) : 2.00-5.00 (13H, m) ; 6.38-8.20 (9H, m) ; 10.80 (IH, s) MASS : 568 (M+l), 456
Example 5-12)
[α]2 ) 2 : -10.4° (C=0.5, MeOH)
IR (Nujol) : 3650-3100, 2750-2000, 1635, 1277, 1130 cm"1 NMR (DMSO-d6, δ) : 3.00-5.20 (11H, m) ; 6.60-8.30 (11H, m) ; 10.95 (IH, s) MASS : 568 (M+l) (free), 456
Example 5-13) [α]2 ) 2 : -31.8° (C=0.5, MeOH)
IR (Nujol) : 3270, 2750-2000, 1637, 1531, 1279, 1124,
964 cm"1 NMR (DMSO-d6, δ) : 2.73-5.15 (14H, m) ; 6.60-8.25
(10H, m) ; 10.89 (IH, s) MASS : 646 (M+l) (free), 568, 456
Example 5-14)
[ ]g3 : 11.8° (C=0.5, MeOH)
IR (Nujol) : 3650-3100, 1625, 1543, 1275, 1130 cm"1 NMR (DMSO-d6, δ) : 2.09-2.11 (3K, m) ; 2.52-5.00 (11H, m) , 6.63-8.20 (9H, m) ; 10.85 (IH, s) ; 12.07 (IH, s) MASS : 638 (M+l) ,- 456
Example 5-15) [α]J8 : -51.6° (C=0.5, MeOH)
IR (Nujol) : 3650-3100, 2750-2000, 1634, 1540, 1274,
1170, 1127, 900 cm"1 NMR (DMSO-d6, δ) : 2.31 (3H, s) ; 2.73-5.35 (11H, m) ;
6.63-8.25 (8H, m) ; 10.94-11.00 (IH, m) ; 13.20 (IH, MASS : 611 (M+ l ) ( free )
Example 5-16) [α]§2 : -23.4° (C=0.5, MeOH)
IR (Nujol) : 3650-3000, 2750-2000, 1620, 1274, 1175,
1128, 900 cm"1 NMR (DMSO-d6, δ) : 1.10 (3H, t, J=7.2Hz), 2.60-5.10
(16H, m) ; 6.50-8.21 (9H, m) ; 10.91 (IH, s) ; 11.50- 11.90 (IH, br s)
MASS : 638 (M+l) (free)

Claims

1. A compound of the formula:
or fumaric acid salt thereof.
2. The compound of claim 1, which is the compound of the formula :
3. A process for preparing a compound of the formula :
or fumaric acid salt thereof,
which comprises
(1) reacting a compound of the formula :
or its reactive derivative at the carboxy group or a salt thereof with a compound of the formula : or its reactive derivative at the amino group
or a salt thereof to give a compound of the formula :
or fumaric acid salt thereof, or
(2) reacting a compound of the formula :
or a salt thereof other than fumaric acid salt thereof with fumaric acid to give a compound of the formula :
4. A pharmaceutical composition comprising a compound of claim 1 as an active ingredient, in association with a pharmaceutically acceptable, substantially non-toxic carrier or excipient.
5. A method for treating or preventing Tachykinin-mediated diseases which comprises administering an effective amount of a compound of claim 1 to human being or animals.
6. A compound of claim 1 for use as a medicament.
7. Use of a compound of claim 1 for manufacture of a
medicament for treating or preventing Tachykinin- mediated diseases.
8. A compound of the following general formula:
wherein
R1 is trihalo (lower) alkyl,
R2 is trihalo (lower) alkyl,
R3 is indolyl (lower) alkyl,
in which
R5 is hydrogen or lower alkoxycarbonyl,
R6 is hydrogen or lower alkanoyl,
R7 is hydrogen, lower alkyl, lower alkanoyl, lower alkoxycarbonyl, lower alkoxy (lower) alkanoyl, cyclo (lower) alkylcarbonyl, aroyl or lower alkylsulfonyl,
or its pharmaceutically acceptable salt.
EP96915200A 1995-05-25 1996-05-21 1-benzoyl-2-(indolyl-3-alkyl)-piperazine derivatives as neurokinin receptor antagonists Ceased EP0846116A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45017695A 1995-05-25 1995-05-25
US450176 1995-05-25
PCT/JP1996/001335 WO1996037489A1 (en) 1995-05-25 1996-05-21 1-benzoyl-2-(indolyl-3-alkyl)-piperazine derivatives as neurokinin receptor antagonists

Publications (1)

Publication Number Publication Date
EP0846116A1 true EP0846116A1 (en) 1998-06-10

Family

ID=23787083

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96915200A Ceased EP0846116A1 (en) 1995-05-25 1996-05-21 1-benzoyl-2-(indolyl-3-alkyl)-piperazine derivatives as neurokinin receptor antagonists

Country Status (14)

Country Link
EP (1) EP0846116A1 (en)
JP (1) JP3071829B2 (en)
KR (1) KR19990021857A (en)
CN (1) CN1072220C (en)
AU (1) AU706021B2 (en)
CA (1) CA2222041A1 (en)
EA (1) EA000669B1 (en)
HU (1) HUP9900822A3 (en)
IL (1) IL118369A (en)
NZ (1) NZ307625A (en)
TR (1) TR199600438A2 (en)
TW (1) TW391960B (en)
WO (1) WO1996037489A1 (en)
ZA (1) ZA964101B (en)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2189501A1 (en) * 1995-11-06 1997-05-07 Harry R. Howard Nk-1 receptor antagonists for the treatment of cancer
AU714931B2 (en) * 1995-12-18 2000-01-13 Fujisawa Pharmaceutical Co., Ltd. Piperazine derivatives as tachykinin antagonists
AUPO735997A0 (en) * 1997-06-17 1997-07-10 Fujisawa Pharmaceutical Co., Ltd. Piperazine derivatives
DE19824865A1 (en) * 1997-08-27 1999-03-04 Solvay Pharm Gmbh New urea derivatives
EP0899270B1 (en) * 1997-08-27 2008-05-21 Solvay Pharmaceuticals GmbH Indolylmethyl-N,N'-bisacylpiperazines as neurokinine receptor antagonists
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
DK1246806T3 (en) 1999-11-03 2008-06-16 Amr Technology Inc Aryl and heteroaryl-substituted tetrahydroisoquinolines and their use in blocking the reuptake of norepinephrine, dopsmin and serotonin
WO2002004455A2 (en) 2000-07-11 2002-01-17 Albany Molecular Research, Inc 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof
DE10036818A1 (en) * 2000-07-28 2002-02-07 Solvay Pharm Gmbh New N-Triazolylmethyl-Piperazine Derivatives as Neurokinin Receptor Antagonists
UA75425C2 (en) 2001-07-09 2006-04-17 Piperazine oxime derivatives with antagonistic activity to nk-1 receptor, use thereof, a pharmaceutical composition based thereon, a method for producing and a method for producing intermediary compounds
UA77515C2 (en) 2002-04-04 2006-12-15 Diazabicyclo alkane derivatives possessing neuroldnin-nk1 receptor antagonistic activity
KR101389246B1 (en) 2004-07-15 2014-04-24 브리스톨-마이어스스퀴브컴파니 Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
WO2006072436A1 (en) * 2005-01-07 2006-07-13 F. Hoffmann-La Roche Ag [4-(heteroaryl) piperazin-1-yl]-(2,5-substituted -phenyl)methanone derivatives as glycine transporter 1 (glyt-1) inhibitors for the treatment of neurological and neuropsychiatric disorders
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
NZ565111A (en) 2005-07-15 2011-10-28 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
KR20080048502A (en) 2005-09-29 2008-06-02 머크 앤드 캄파니 인코포레이티드 Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
JP5489333B2 (en) 2006-09-22 2014-05-14 メルク・シャープ・アンド・ドーム・コーポレーション Methods of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
CA2674436C (en) 2007-01-10 2012-07-17 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
AU2008208920A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or R(-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an NK1
AU2008233662B2 (en) 2007-04-02 2012-08-23 Msd K.K. Indoledione derivative
WO2008147864A2 (en) * 2007-05-22 2008-12-04 Xenon Pharmaceuticals Inc. Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions
EP2170076B1 (en) 2007-06-27 2016-05-18 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
AU2009222122A1 (en) 2008-03-03 2009-09-11 Tiger Pharmatech Tyrosine kinase inhibitors
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
AU2010247763B2 (en) 2009-05-12 2015-12-24 Albany Molecular Research, Inc. 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof
ES2528404T3 (en) 2009-05-12 2015-02-10 Bristol-Myers Squibb Company Crystal forms of (S) -7 - ([1,2,4] triazol [1,5-a] pyridin-6-yl) -4- (3,4-dichlorophenyl) -1,2,3,4- tetrahydroisoquinoline and its uses
ES2446971T3 (en) 2009-05-12 2014-03-11 Albany Molecular Research, Inc. Tetrahydroisoquinolines substituted with aryl, heteroaryl, and heterocycle and their use
US8859776B2 (en) 2009-10-14 2014-10-14 Merck Sharp & Dohme Corp. Substituted piperidines that increase p53 activity and the uses thereof
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
CA2805265A1 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
HRP20191232T1 (en) 2010-08-17 2019-11-01 Sirna Therapeutics Inc RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
US8946216B2 (en) 2010-09-01 2015-02-03 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
DK2632472T3 (en) 2010-10-29 2018-03-19 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
AU2012245455A1 (en) 2011-04-21 2013-10-31 Merck Sharp & Dohme Corp. Insulin-Like Growth Factor-1 Receptor inhibitors
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP2844261B1 (en) 2012-05-02 2018-10-17 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
JP6280554B2 (en) 2012-09-28 2018-02-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Novel compounds that are ERK inhibitors
AU2013352568B2 (en) 2012-11-28 2019-09-19 Merck Sharp & Dohme Llc Compositions and methods for treating cancer
KR102196882B1 (en) 2012-12-20 2020-12-30 머크 샤프 앤드 돔 코포레이션 Substituted imidazopyridines as hdm2 inhibitors
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
WO2019094312A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
CN112805006B (en) 2018-08-07 2024-09-24 默沙东有限责任公司 PRMT5 inhibitors
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors
EP3833668B1 (en) 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Prmt5 inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0411150T3 (en) * 1989-02-10 1996-12-16 Otsuka Pharma Co Ltd indole derivatives
IL111730A (en) * 1993-11-29 1998-12-06 Fujisawa Pharmaceutical Co Piperazine derivatives processes for the preparation thereof and pharmaceutical compositions containing the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9637489A1 *

Also Published As

Publication number Publication date
TW391960B (en) 2000-06-01
IL118369A0 (en) 1996-09-12
EA000669B1 (en) 2000-02-28
IL118369A (en) 2000-06-01
TR199600438A2 (en) 1996-12-21
JPH11505830A (en) 1999-05-25
AU5703196A (en) 1996-12-11
CA2222041A1 (en) 1996-11-28
HUP9900822A2 (en) 1999-06-28
NZ307625A (en) 1999-02-25
HUP9900822A3 (en) 1999-11-29
ZA964101B (en) 1996-07-29
AU706021B2 (en) 1999-06-03
JP3071829B2 (en) 2000-07-31
KR19990021857A (en) 1999-03-25
EA199700425A1 (en) 1998-12-24
CN1191533A (en) 1998-08-26
WO1996037489A1 (en) 1996-11-28
CN1072220C (en) 2001-10-03

Similar Documents

Publication Publication Date Title
EP0846116A1 (en) 1-benzoyl-2-(indolyl-3-alkyl)-piperazine derivatives as neurokinin receptor antagonists
EP0655442B1 (en) Piperazine derivatives as Tachykinin antagonists
US6087357A (en) Piperazine derivatives as tachykinin antagonists
RU2258702C2 (en) Derivatives of aroylpiperazine, method for their preparing, pharmaceutical composition based on thereof and method for treatment
AU3904593A (en) Peptides having tachykinin antagonist activity
CA2033363A1 (en) Quinazoline derivatives and their preparation
US5939413A (en) Piperazine derivatives
US5883098A (en) Piperazine derivatives
US5654400A (en) Process for making peptide compounds having tachykinin antagonistic activity
MXPA97009079A (en) Derivatives of 1-benzol-2- (indolil-3-alkyl) piperazine as antagonists of the neuroquin receiver
AU743723B2 (en) Aroyl-piperazine derivatives, their preparation and their use as tachykinin antagonists
MXPA98004887A (en) Piperazine derivatives as taquicin antagonists
MXPA99011778A (en) Aroyl-piperazine derivatives, their preparation and their use as tachykinin antagonists

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19971128

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 20010219

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20021102

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1008990

Country of ref document: HK